
CURRICULUM VITÆ



PERSONAL INFORMATIONS

Name	**MARIO FERRAIOLI**
Address	
Phone	
E-mail	**mario.ferraioli@unicamillus.org**
PEC	**ferraioli.mario@pec.ordinemedicisalerno.it**
Place and date of birth	
Nationality	**Italian**
Italian Medical Registration	**OMCEO Salerno, n°= 11389**
General Medical Council Reference Number (UK)	**8107636**

CURRENT POSITION

1 October 2026 - ongoing

Professor of Rheumatology (untenured) - UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy

20 November 2023 - ongoing

OMERACT Synovial Tissue Biopsy Study Group; Fellow Member. Activities include collaboration with experts and patient partners to support:

- Evaluation and validation of outcome instruments
- Research outputs (abstracts, presentations, publications)
- Meetings and working group operations

3 November 2023 - ongoing (end date Nov 2026)

PhD Student in MIMIT (Microbiologia, Immunologia, Malattie Infettive, Trapianti D'organo e Patologie Connesse)
University of Rome Tor Vergata - Rome, Italy
Activities, together with research, include teaching undergraduate students both in Italian and English

EDUCATION and PROFESSIONAL EXPERIENCES

16 June 2025 - 15 June 2026 — Clinical Research Fellow - School of Infection and Immunity, College of Medical Veterinary and Life Sciences, University of Glasgow (UK)

7 November 2023 - 7 November 2024 — PARTNER fellow (Research Assistant)
Sir Graeme Davies Building, Institute of Infection and Immunity, College of Medical Veterinary and Life Sciences, University of Glasgow (UK)

3 November 2023 — Specialist degree in Rheumatology
Università degli Studi di Roma Tor Vergata - Rome (IT)
Thesis: Efficacy and safety of anti-SARS-CoV-2 vaccination in Systemic Lupus Erithematosus patients
Final grade: 50/50 *summa cum laude*

1 November 2019 - 3 November 2023 — Registrar in Rheumatology,
University of Rome Tor Vergata - Rome, Italy
During this course, he attended following structures:

- U.O.C. Reumatologia presso Ospedale San Camillo-Forlanini Roma from February 1, 2021 to August 31, 2021
- U.O.C. Reumatologia Pediatrica presso Ospedale Pediatrico Bambino Gesù, Roma
  from March 1, 2022 to August 31, 2022
- Biopsy Unit presso U.O.C. Reumatologia Policlinico A. Gemelli, Rome, Italy
  From December 1, 2022 to April 30, 2023

12 February 2019 — Passed Italian state medical board exam

25 July 2018 — Degree in Medicine and Surgery,
Facoltà di Medicina e Psicologia, University "La Sapienza" - Rome, Italy
Thesis: Comparison of Peripheral Facial Nerve Palsy Grading Systems Using a Novel AI-Based Digital Video Analysis System
Final grade: 110/110 *summa cum laude*

REFINEMENT'S COURSES

20 - 21 January 2023 — SONO MASTER - an OMERACT Ultrasound initiative, Rome (Italy)
Scientific director Prof. Maria Antonietta D'Agostino

20 - 22 October 2022 — Musculoskeletal Ultrasound in Rheumatology, Roma (Italy)
Scientific director Prof. Annamaria Iagnocco

8 - 10 December 2021 — Primary Vasculitis, Reggio Emilia (Italy)
Scientific director Prof. Carlo Salvarani

PERSONAL SKILLS

	Excellent knowledge of Microsoft Office, including: Word, Excel, Power Point and Access
	Excellent knowledge in GraphPad - Prism v 8.0.2
	Excellent knowledge in IBM SPSS Statistics v29.0.2.0
Mother tongue	Italian
Other languages	English, IELTS Academic test (12/7/2023) **overall grade = 8**
	Speaking: C2; Writing: C2

SCIENTIFIC PRODUCTION

Articles on indexed journals	**17, period 2019 – 2026**
Hirsh Index (H), Scopus	**9**
Total citations	**195**
Meeting abstracts	14
Relazioni a congressi	7
Rewiever per riviste indicizzate	17

PUBLICATIONS ON INDEXED JOURNALS

1. Chimenti MS, D'Antonio A, Conigliaro P, Ferrigno S, Vendola A, **Ferraioli M.** et al. An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis. Biologics. 2020 Aug 20;14:53-75. doi: 10.2147/BTT.S260754. PMID: 32903867; PMCID: PMC7445514.
2. Iacoella C, De-Giorgio F, Palaia G, **Ferraioli M**, Arcangeli A, Ralli M. Evaluation of General Health Status of Persons Living in Socio-Economically Disadvantaged Neighborhoods in a Large European Metropolitan City. Appl. Sci. 2022, 12, 7428. https://doi.org/10.3390/app12157428
3. Chimenti MS, Perricone C, D'Antonio A, **Ferraioli M**, et al. Genetics, Epigenetics, and Gender Impact in Axial-Spondyloarthritis Susceptibility: An Update on Genetic Polymorphisms and Their Sex Related Associations. Front Genet. 2021 Aug 10;12:671976. doi: 10.3389/fgene.2021.671976.
4. Petrone L, Picchianti-Diamanti A, Sebastiani GD, Aiello A, Laganà B, Cuzzi G, Vanini V, Gualano G, Grifoni A, **Ferraioli M**, Castilletti C, Meschi S, Vaia F, Nicastri E, Sette A, Goletti D. Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases. Int J Infect Dis. 2022 Aug;121:24-30. doi: 10.1016/j.ijid.2022.04.027. Epub 2022 Apr 22.
5. Ramonda R, Lorenzin M, Chimenti MS, D'Angelo S, Marchesoni A, Salvarani C, Lubrano E, Costa L, Dal Bosco Y, Fracassi E, Ortolan A, **Ferraioli M**, et al. Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. Ther Adv Musculoskelet Dis. 2022 Apr 29;14:1759720X221090310. doi: 10.1177/1759720X221090310.
6. Picchianti Diamanti A, Navarra A, Aiello A, Laganà B, Cuzzi G, Salmi A, Vanini V, Maggi F, Meschi S, Matusali G, Notari S, Agrati C, Salemi S, Di Rosa R, Passarini D, Di Gioia V, Sesti G, Conti F, Spinelli FR, Corpolongo A, Chimenti MS, **Ferraioli M**, et al. Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine. Vaccines 2023, 11(11), 1684; https://doi.org/10.3390/vaccines11111684
7. Scriffignano, S., Perrotta, F. M., Conigliaro, P., Ferraioli, M., Triggianese, P., Chimenti, M. S., & Lubrano, E. (2023). Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis. Rheumatology and therapy, 10.1007/s40744-023-00588-4. Advance online publication. https://doi.org/10.1007/s40744-023-00588-4
8. Picchianti Diamanti A, Navarra A, Cuzzi G, Aiello A, Salemi S, Di Rosa R, De Lorenzo C, Vio D,

Sebastiani G, **Ferraioli M**, Benucci M, Li Gobbi F, Cantini F, Polidori V, Simmaco M, Cialdi E, Scolieri P, Bruzzese V, Nicastri E, D'Amelio R, Laganà B, Goletti D. The Third Dose of BNT162b2 COVID-19 Vaccine Does Not "Boost" Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis. Biomedicines. 2023 Feb 23;11(3):687. doi: 10.3390/biomedicines11030687.

9. Perrotta FM, Scriffignano S, Triggianese P, **Ferraioli M.** et al. Sensitivity and specificity of composite indices of remission in males and females with psoriatic arthritis: a multicenter cross-sectional study of longitudinal cohorts. J Rheumatol. 2023 Dec 15:jrheum.2023-0786. doi: 10.3899/jrheum.2023-0786.
10. Conigliaro P, D'Antonio A, Wlderk A, Sabuzi F, **Ferraioli M.** et al. Clinical and imaging findings in enteropathicspondyloarthritis with special emphasize indiagnostic delay: a cross-sectional study. Ther Adv Chronic Dis 2024, Vol. 15: 1-16 DOI: 10.1177/20406223241229843
11. **Ferraioli M**, Fiannacca L, Greco E, Cela E, Fatica M, Bergamini A, Chimenti MS. Risankizumab Efficacy in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Remission: A Case Report on Rheumatologic and Dermatologic Disease Manifestations with Literature Review. Case Reports Immunol. 2024 Mar 19;2024:9076852. doi: 10.1155/2024/9076852.
12. Ramonda R, Lorenzin M, Chimenti MS, D'Angelo S, Marchesoni A, Selmi C, Lubrano E, Santo L, Luchetti Gentiloni MM, Atzeni F, Cauli A, Manara M, Rossini M, Foti R, Cozzi G, Scagnellato L, **Ferraioli M**, et al. (2024). Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis. Frontiers in immunology, 15, 1435599. https://doi.org/10.3389/fimmu.2024.1435599
13. Caso F, Fatica M, **Ferraioli M**, et al. The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis. Expert Opin Biol Ther. Published online July 26, 2024. doi:10.1080/14712598.2024.2384090
14. Ramonda R, Lorenzin M, Chimenti MS, Atzeni F, Semeraro A, D'Angelo S, Selmi C, Ortolan A, Marchesoni A, Manara M, Luchetti Gentiloni MM, Santo L, Salvarani C, Cauli A, Rossini M, Amato G, Cozzi G, Scagnellato L, **Ferraioli M**, et al. (2024). Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort. Arthritis research & therapy, 26(1), 172. https://doi.org/10.1186/s13075-024-03401-x
15. Fatica M, Çela E, **Ferraioli M**, Costa L, Conigliaro P, Bergamini A, Caso F, Chimenti MS. The Effects of Smoking, Alcohol, and Dietary Habits on the Progression and Management of Spondyloarthritis. J Pers Med. 2024 Nov 21;14(12):1114. doi: 10.3390/jpm14121114.
16. **Ferraioli M,** Levani J, De Luca R, Matucci-Cerinic C, Gattorno M, Guiducci S, Bellando Randone S, Chimenti MS. What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review. J. Clin. Med. 2025, 14, 1366. https://doi.org/10.3390/jcm14041366
17. **Ferraioli M,** Aiello A, Prevete I, et al. Anti-SARS-CoV-2 immune response persists 12 months after mRNA vaccination with BNT162b2 in Systemic Lupus Erythematosus patients. Vaccines. 2025; accepted for publication on April 4, 2025.
18. **Ferraioli M**, Small A, Alivernini S, Fonseca JE, Just SA, Maksymowych W, Morton F, Nicorescu I, Orr C, Perniola S, Pratt A, Romão VC, van de Sande MGH, Strand V, Tas SW, Veale D, Wechalekar MD, Najm A; OMERACT Synovial Tissue Biopsy Special Interest Group. Interobserver variability in synovial tissue biopsy markers in Rheumatoid Arthritis: Results from OMERACT special interest group on synovial tissue biopsy. Semin Arthritis Rheum. 2026 Oct;80:153041. doi: 10.1016/j.semarthrit.2026.153041. Epub 2026 Jun 30. PMID: 42456234.

MEETING ABSTRACTS

1. M.S. Chimenti, **M. Ferraioli**, A. D'antonio, P. Conigliaro, S. Ferrigno, A. Vendola, P. Triggianese, G. L. Fonti, R. Perricone. How do we treat psoriatic arthritis? evidence from a 15-year monocentric bdmards experience. AB0754 Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1670
2. S. Scriffignano, F.M. Perrotta, M. Fatica, Paola Triggianese, Paola Conigliaro, **M. Ferraioli**, Characterizing the Minimal Disease Activity domains achieved based on different treatments. Annals of the Rheumatic Diseases 2023;82:1798.
3. A. D'antonio, M. S. Chimenti, P. Conigliaro, P. Triggianese, S. Ferrigno, **M. Ferraioli**, et al. Impact of gender and comorbidities in enterophatic spondyloarthritis: a cross-sectional study. POS0231 Ann Rheum Dis, volume 80, supplement 1, year 2021, page 335
4. P.Triggianese, A. D'antonio, E. Cela, B. Kroegler, S. Modica, **M. Ferraioli**, et al. Autoimmunity profile and lung involvement in italian patients with dermatomyositis during covid-19 pandemia. AB1187 Ann Rheum Dis volume 81, supplement 1, year 2022, page 1708
5. G. Cozzi, M. Lorenzin, M. S. Chimenti, S. D'angelo, A. Marchesoni, C. Salvarani, E. Lubrano, L. Costa, Y. Dal Bosco, E. Fracassi, A. Ortolan, **M. Ferraioli. et al.** Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. POS0297 Ann Rheum Dis volume 81, supplement 1, year 2022, page 395
6. S. Scriffignano, F.M. Perrotta, M. Fatica, P. Triggianese, P. Conigliaro, **M. Ferraioli**, M.S. Chimenti, E. Lubrano. Patient Acceptable Symptoms State in Psoriatic Arthritis: does it differ between sexes? Annals of the Rheumatic Diseases 2023;82:1796.
7. **M. Ferraioli**, L. De Marco, L. Fiannacca, M. Iacovantuono, B. Monosi, P. Triggianese, P. Conigliaro, A. Bergamini, M.S. Chimenti. Long Covid in Rheumatoid arthritis and in Psoriatic arthritis: clinical pattern and gender-based differences from a single-centre case-control study. Annals of the Rheumatic Diseases 2023;82:545.
8. **M. Ferraioli**, P. Conigliaro, C. Bonini, S. Ferrigno, M. Teoli, C. Paganini, V. Maffei, M. Galluzzo, M. Talamonti, A. Bergamini, M.S. Chimenti. Cutaneous Lupus Erithematosus over the COVID major pandemic period, incidence and clinical characteristics. Annals of the Rheumatic Diseases 2023;82:1537
9. **Ferraioli M**, Fiannacca L, Greco E, Cela E, Fatica M, Bergamini A, Chimenti MS. Risankizumab efficacy in SAPHO syndrome: a case report on rheumatologic and dermatologic disease manifestations. Accepted poster presentation at 2024 EULAR congress.
10. **Ferraioli M**, Prevete I, Chimenti MS, et al. AB0077 Immunogenicity And Safety Prospective Study Of Anti-Sars-Cov-2 Mrna Vaccination In A Real-Life Setting Of Systemic Lupus Erythematosus Patients. Annals of the Rheumatic Diseases 2024;83:1268-1269.
11. **Ferraioli M,** Immune suppressive drugs have a minor impact on SARS-CoV-2-specific immune response in Systemic Lupus Erythematosus patients: results from a prospective longitudinal case-control study on BNT162b2 mRNA vaccination. Congresso SIR 2024, Rimini 27-30 November 2025
12. **Ferraioli M,** Influenza della pandemia da SARS-CoV-2 sul Lupus Eritematoso Cutaneo, dati da una coorte multicentrica. Congresso SIR 2024, Rimini 27-30 November 2025
13. **Ferraioli M,** Alivernini S, Fonseca JE, Just SA, Morton F, Nicorescu I, Perniola S, Pratt A, Romão VC, van de Sande M.G.H., Small A, Strand V, Tas SW, Veale D, Wechalekar MD, Najm A, on behalf of OMERACT Special Interest Group on Synovial Tissue Biopsy. Interobserver variability in synovial tissue biopsy markers: results from OMERACT Special Interest Group on Synovial Tissue Biopsy. Annals of the Rheumatic Diseases, 84, 1397-1398. https://doi.org/10.1016/j.ard.2025.06.714

14. **Ferraioli M,** Turri M, Ripiccini S, Conigliaro P, Çela E, Ferrigno S, Monosi B, Chimenti MS. Baseline clinical signatures and comorbidities predict Treatment-Refractory and Difficult-To-Manage Psoriatic Arthritis: a real-life cohort study. Submitted to the 2026 Società Italiana di Reumatologi (SIR) congress; Rimini 25-28 Nov 2026.

ORAL COMMUNICATIONS

1. **Ferraioli M.** Incidence and clinical characteristics of Long Covid in Psoriatic Arthritis patients**.** 2022 Joint in Rheumatology, 14-15th October 2022, Rome.
2. **Ferraioli M.** Long Covid in Psoriatic arthritis and in Rheumatoid arthritis: gender-based difference from a case-control study. Prof. Yehuda Shoenfeld's Friday Mosaic of Autoimmunity International meeting #135. Friday, 17th March 2023 .
3. **Ferraioli M.** Efficacy and safety of anti-SARS-CoV-2 vaccination in Systemic Lupus Erithematosus patients. "Vaccinazioni nei pazienti con malattie reumatologiche" Congress, Milan 15 September 2023
4. **Ferraioli M.** Efficacy and safety of anti-SARS-CoV-2 vaccination in Systemic Lupus Erithematosus patients. 2023 Joint in Rheumatology, 26-27th October 2023, Rome, (IT).
5. **Ferraioli M.** Le comorbidità dell'Artrite Psoriasica, Florence Rheumatology Project Area, 28-29 June 2024, Florence, (IT).
6. **Ferraioli M.** Aggiornamento sulla Fisiopatologia della PsA, Reuma Siena 2024, 21-23 November 2024, Siena (IT)
7. **Ferraioli M.** Anti-TNF, anti-IL17m anti-IL12/23: quale strategia nell'artrite psoriasica? Incontri reumatologici romani 2025, Roma 21 Febbraio 2025

REWIEVER FOR INTERNATIONAL INDEXED JOURNALS

1. Hormaza-Jaramillo A, Hurtado-Bermudez LJ, Peñaloza Gonzalez D, Delgado-Mora T. High persistence of biologic therapy in patients with Psoriatic arthritis: a real-world evidence from a high-complexity hospital in Colombia. Front Pharmacol. 2025 Aug 29;16:1559168. doi: 10.3389/fphar.2025.1559168. Reviewed on 1 August 2025
2. Efficacy of Iguratimod based therapy for the treatment of SAPHO syndrome, *Therapeutic Advances in Musculoskeletal Disease.* Rejected, reviewed *on* 8 August 2025
3. Cognitive function, fibromyalgia, mood disorders, sleep quality and quality of life in patients with SAPHO syndrome: a cross-sectional study in China. Musculoskeletal Care, 1 December 2025.
4. Jin D, Xu MY, Wang XL, Wang RQ, Tang JT and Liu YQ (2026) Case Report: Successful management of refractory SAPHO syndrome with guselkumab-upadacitinib combination. *Front Immunol.* 17:1745464. doi: 10.3389/fimmu.2026.1745464

4 Real-World Performance of GRAPPA and EULAR Definitions of Difficult-to-Treat (D2T) Psoriatic Arthritis: Insights from the ORCHESTRA Cohort. Ther Adv in MSK care. 2 December 2025

5. SAPHO Syndrome Mimicking Septic Arthritis in a Patient with Hidradenitis Suppurativa Clinical Case Reports. 5 December 2025
6. Biological and targeted synthetic treatment of SAPHO syndrome - systematic review Authors: Wroński J, Adamska A, Urba J et al. Polish Archives of Internal Medicine, Ms. No. PAIM-25-00347. 13 December 2025.
6. "Partial Bull-Head Sign": SAPHO Syndrome, BMJ Case Reports (Manuscript ID: bcr-2026-272165). Reviewed on 31 January 2026.

7. Infectious pubic symphysitis: An atypical infection not to be overlooked. Clinical Case Reports, reviewed on 23 February 2026.
8. Case Report: Erythema Annulare Centrifugum as a Novel Cutaneous Manifestation of SAPHO Syndrome Responsive to Tofacitinib. Jinwan Du, Liting Huang, Shaohui Geng, Chen Li and Shike Shang. Frontiers in Immunology (Manuscript ID: 1817374). Reviewed on Mar 3, 2026.
9. SAPHO Syndrome Presenting with Severe Inflammatory Back Pain (Sacroiliitis) and Rare Retinol associated Myopathy in an Iraqi adolescent Male: A case report and literature review. Clinical Case Reports (Manuscript ID: CCR3-2026-01-0319); Reviewed on Mar 26, 2026.
10. Matched 34-month MRI observation of chondral defect stabilisation and bone marrow oedema reduction in a normal-weight patient with psoriatic arthritis on tirzepatide monotherapy: a case report and review of incretin agents in inflammatory arthropathy (Manuscript ID: TAB-26-04-148) Ther. Adv. Musculoskelet. Dis; Reviewed on May 17, 2026. Factors Associated with the Occurrence, Resolution, and Recurrence of Tender Psoriatic Dactylitis: Results from a Longitudinal Cohort Study. (Manuscript ID: TAB-26-05-160). Ther. Adv. Musculoskelet. Dis; Reviewed on June 4, 2026.
11. Factors Associated with the Occurrence, Resolution, and Recurrence of Tender Psoriatic Dactylitis: Results from a Longitudinal Cohort Study. (Manuscript ID: TAB-26-05-160). Ther. Adv. Musculoskelet. Dis; Reviewed on June 4, 2026.
12. The great mimicker: chronic articular adult-onset Still's disease presenting as spondyloarthritis with macrophage activation syndrome. (Manuscript ID: bcr-2026-274504). BMJ Case report. Reviewed on June 5, 2026.
13. Zhao D, Du J, Man R, Geng S, Shang S and Li C (2026) Case report of three cases and literature review: is follicular occlusion triad with peripheral/axial spondyloarthritis involvement an analog of SAPHO syndrome?. Front. Med. 13:1876061. doi: 10.3389/fmed.2026.1876061 Reviewed on June 11, 2026.
14. Xia R, Gao K, Zhao Y, Lin Y, Yang Q and Xu W (2026) SAPHO syndrome and pustular skin diseases: shared inflammatory circuits, divergent tissue outcomes, and the limits of a spectrum model. Front. Immunol. 17:1906728. doi: 10.3389/fimmu.2026.1906728
15. Cutaneous phenotype-stratified treatment patterns and outcomes in pediatric SAPHO syndrome: a single-center retrospective study". Wang Z, Zhang Y, Liang Y, Shen C, Chen Y, Miao C, et al. Acta Dermato-Venereologica.
16. Humoral immune response to SARS-CoV-2 vaccination in Tunisian patients receiving immunosuppressive therapy: an observational study from the BIOVAX cohort. Bourguiba R, Ayari M, Dridi K et al. Health Science Reports, article details: ID 4617577

PRIZES AND AWARDS

1. "Premio Prof. Roberto Perricone 2023". Joint in Rheumatology, 26-27th October 2023, Rome (€ 500).
2. PARTNER fellowship Program 2023 (€ 50.000)
3. FOREUM Fellowship grant 2025 (€ 50.000)

Rome, 1 October 2026